Anne Lesage initiated GrayMatters Consulting in 2010. She advises scientific teams and engages in interim positions to develop and leverage assets towards valorization. She applies a rigorous bottom up analysis of risks and opportunities. She focusses and optimizes the value of technology platforms and drug development projects and translates their benefit to prospective customers. She is experienced in due diligence, risk assessment, gap analysis, designing and leading cost-effective strategies towards exits, program management and business development. She acquired and structured business contracts for clients with big and mid-sized pharma in Asia, Europe and USA. Anne is an independent consultant and advisor to startups, biotech, venture capital firms, technology transfer offices and governmental agencies.